[29] showed that patients with NPM1 myeloid neoplasm (less than 20% blasts)—majority represented by cases of MDS with excess blasts, chronic myelomonocytic leukemia (CMML), and MDS/MDS/myeloproliferative (MDS/MPN) neoplasms—had paradoxically inferior overall survival when compared with cases of NPM1 AML (more than 20% of blasts). The gene discussed is NPM1; the disease is myeloid neoplasm.